Scroll Back to Top
Accessibility
Accessibility
<span>The evolving role of MRD in solid tumors: Progress and potential</span>
March 26, 2026

The evolving role of MRD in solid tumors: Progress and potential

Molecular residual disease (MRD) testing is transforming cancer care by offering a more precise way to monitor treatment outcomes. MRD refers to trace amounts of tumor-derived materials, such as cells, nucleic acids, and proteins, that remain in the body after therapy. While MRD testing is well-established in hematologic malignancies, it is increasingly being explored for solid tumors to evaluate disease recurrence and treatment response. 
Read more »
<span>Fast-tracking multi-CDx validation for global drug development</span>
March 26, 2026

Fast-tracking multi-CDx validation for global drug development

Multi companion diagnostic (CDx) validation is crucial for advancing precision medicine in global drug development. By verifying that diagnostic tests accurately identify patients likely to benefit from specific treatments, CDx validation enables targeted therapies and personalized medicine. This process often involves validating multiple assays that detect distinct biomarkers, each linked to different therapeutic approaches or disease subtypes. When done effectively, this multi-CDx validation contributes to better patient stratification, streamlined clinical trial execution and improved regulatory alignment across regions.
Read more »
March 12, 2026

Executive Summary: The Pulse of the Oncologist

We surveyed 152 U.S. oncologists and analyzed industry data to uncover five urgent trends shaping oncology in 2026. These insights reveal where diagnostic partners can make the greatest impact, helping clinicians reclaim time and deliver care that’s smarter, faster and more connected. This executive summary provides a snapshot of the full report.
Read more »

Molecular Tumor Board: 68-year-old female with invasive ductal carcinoma of the right breast

In this molecular tumor board discussion, our Medical Affairs team reviews a case of de novo metastatic breast cancer where they emphasize the importance of comprehensive biomarker assessment, including hormone receptor and HER2 biomarkers in guiding therapeutic strategy. Additionally, the discussion highlights the growing role of liquid biopsy in identifying resistance mechanisms and optimizing treatment selection in advanced metastatic breast cancer.

Read more »
Subscribe to